Pharmaceutical intermediates
VONOPRAZAN FUMARATE Intermediates
11 pharmaceutical intermediates for VONOPRAZAN FUMARATE. Indication: Helicobacter Pylori Infection; Esophagitis; Gastroesophageal Reflux Disease.
About VONOPRAZAN FUMARATE
- Originator
- Takeda Pharmaceuticals
- Indication
- Helicobacter Pylori Infection; Esophagitis; Gastroesophageal Reflux Disease
- Approved Date
- 05/03/2022
- NCE Patent
- 05/03/2027
- DS/DP
- 08/11/2025
Available intermediates
11 intermediates currently listed for VONOPRAZAN FUMARATE. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 5-(2-fluorophenyl)-1H-pyrrole-3-carbonitrile | 1240948-77-9 | / | / |
| 2-chloro-5-(2-fluorophenyl)-1H-pyrrole-3-carbonitrile | 1240948-72-4 | / | / |
| 5-(2-fluorophenyl)-1H-pyrrole-3-carboxylic acid methyl ester | 1240949-59-0 | / | / |
| 2-[2-(2-Fluorophenyl)-2-oxoethyl]propanedinitrile | 312307-38-3 | / | / |
| pyridine-3-sulfonyl chloride | 16133-25-8 | / | / |
| 1H-Pyrrole-3-carboxylic acid, 5-(2-fluorophenyl)-, ethyl ester | 881674-06-2 | / | / |
| 5-(2-Fluorophenyl)-1H-pyrrole-3-carbaldehyde | 881674-56-2 | / | / |
| 5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carbaldehyde | 881677-11-8 | / | / |
| Vonoprazan | 881681-00-1 | / | / |
| 3-Pyridinesulfonyl chloride | 16133-25-8 | / | / |
| 5-(2-fluorophenyl)-1H-Pyrrole-3-carboxaldehyde | 881674-56-2 | / | / |
Building toward VONOPRAZAN FUMARATE?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →